Altimmune, Inc.
Altimmune, Inc. (ALT) Stock Overview
Explore Altimmune, Inc.’s financial performance, market position, analyst ratings, and future outlook.
ALT Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Altimmune, Inc. (ALT) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $5.38.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -3.05 and a market capitalization of 292.4M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Analyst Recommendations
Price Targets
Company Profile
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
Dr. Vipin K. Garg Ph.D.
59
910 Clopper Road, Gaithersburg, MD
2017